摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1R,2R,3S,4R,5S)-4-(2-chloro-6-((R)-cyclopropylcyclobutylmethylamino)-9H-purin-9-yl)-2,3-O-(isopropylidene)bicyclo[3.1.0]hexane | 1399604-36-4

中文名称
——
中文别名
——
英文名称
(1R,2R,3S,4R,5S)-4-(2-chloro-6-((R)-cyclopropylcyclobutylmethylamino)-9H-purin-9-yl)-2,3-O-(isopropylidene)bicyclo[3.1.0]hexane
英文别名
2-chloro-N-[(R)-cyclobutyl(cyclopropyl)methyl]-9-[(1R,2R,4S,5R,6S)-8,8-dimethyl-7,9-dioxatricyclo[4.3.0.02,4]nonan-5-yl]purin-6-amine
(1R,2R,3S,4R,5S)-4-(2-chloro-6-((R)-cyclopropylcyclobutylmethylamino)-9H-purin-9-yl)-2,3-O-(isopropylidene)bicyclo[3.1.0]hexane化学式
CAS
1399604-36-4
化学式
C22H28ClN5O2
mdl
——
分子量
429.95
InChiKey
YPWZPLMUEPPCRE-YRKZSDTESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    30
  • 可旋转键数:
    5
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.77
  • 拓扑面积:
    74.1
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (1R,2R,3S,4R,5S)-4-(2-chloro-6-((R)-cyclopropylcyclobutylmethylamino)-9H-purin-9-yl)-2,3-O-(isopropylidene)bicyclo[3.1.0]hexane 在 Dowex 50 resin 作用下, 以 甲醇 为溶剂, 反应 7.0h, 以74%的产率得到(1R,2R,3S,4R,5S)-4-(2-chloro-6-((R)-cyclopropylcyclobutylmethylamino)-9H-purin-9-yl)bicyclo[3.1.0]hexane-2,3-diol
    参考文献:
    名称:
    Structural Sweet Spot for A1 Adenosine Receptor Activation by Truncated (N)-Methanocarba Nucleosides: Receptor Docking and Potent Anticonvulsant Activity
    摘要:
    A(1) adenosine receptor (AR) agonists display antiischemic and antiepileptic neuroprotective activity, but peripheral cardiovascular side effects impeded their development. SAR study of N-6-cycloalkylmethyl 4'-truncated (N)-methanocarba-adenosines identified 10 (MRS5474, N-6-dicyclopropylmethyl, K-i = 47.9 nM) as a moderately A(1)AR-selective full agonist. Two stereochemically defined N-6-methynyl group substituents displayed narrow SAR; groups larger than cyclobutyl greatly reduced AR affinity, and those larger or smaller than cyclopropyl reduced A(1)AR selectivity. Nucleoside docking to A(1)AR homology model characterized distinct hydrophobic cyclopropyl subpockets, the larger "A" forming contacts with Thr270 (7.35), Tyr271 (7.36), Ile274 (7.39), and carbon chains of glutamates (EL2) and the smaller subpocket "B" forming contacts between TM6 and TM7. 10 suppressed minimal clonic seizures (6 Hz mouse model) without typical rotarod impairment of A(1)AR agonists. Truncated nucleosides, an appealing preclinical approach, have more druglike physicochemical properties than other A(1)AR agonists. Thus, we identified highly restricted regions for substitution around N-6 suitable for an A(1)AR agonist with anticonvulsant activity.
    DOI:
    10.1021/jm300965a
  • 作为产物:
    描述:
    2,6-dichloro-9-((3aR,3bR,4aS,5R,5aS)-2,2-dimethylhexahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxol-5-yl)-9H-purine 、 (R)-cyclopropylcyclobutylmethylamine hydrochloride 在 三乙胺 作用下, 以 甲醇 为溶剂, 以83%的产率得到(1R,2R,3S,4R,5S)-4-(2-chloro-6-((R)-cyclopropylcyclobutylmethylamino)-9H-purin-9-yl)-2,3-O-(isopropylidene)bicyclo[3.1.0]hexane
    参考文献:
    名称:
    Structural Sweet Spot for A1 Adenosine Receptor Activation by Truncated (N)-Methanocarba Nucleosides: Receptor Docking and Potent Anticonvulsant Activity
    摘要:
    A(1) adenosine receptor (AR) agonists display antiischemic and antiepileptic neuroprotective activity, but peripheral cardiovascular side effects impeded their development. SAR study of N-6-cycloalkylmethyl 4'-truncated (N)-methanocarba-adenosines identified 10 (MRS5474, N-6-dicyclopropylmethyl, K-i = 47.9 nM) as a moderately A(1)AR-selective full agonist. Two stereochemically defined N-6-methynyl group substituents displayed narrow SAR; groups larger than cyclobutyl greatly reduced AR affinity, and those larger or smaller than cyclopropyl reduced A(1)AR selectivity. Nucleoside docking to A(1)AR homology model characterized distinct hydrophobic cyclopropyl subpockets, the larger "A" forming contacts with Thr270 (7.35), Tyr271 (7.36), Ile274 (7.39), and carbon chains of glutamates (EL2) and the smaller subpocket "B" forming contacts between TM6 and TM7. 10 suppressed minimal clonic seizures (6 Hz mouse model) without typical rotarod impairment of A(1)AR agonists. Truncated nucleosides, an appealing preclinical approach, have more druglike physicochemical properties than other A(1)AR agonists. Thus, we identified highly restricted regions for substitution around N-6 suitable for an A(1)AR agonist with anticonvulsant activity.
    DOI:
    10.1021/jm300965a
点击查看最新优质反应信息

文献信息

  • Structural Sweet Spot for A<sub>1</sub> Adenosine Receptor Activation by Truncated (N)-Methanocarba Nucleosides: Receptor Docking and Potent Anticonvulsant Activity
    作者:Dilip K. Tosh、Silvia Paoletta、Francesca Deflorian、Khai Phan、Steven M. Moss、Zhan-Guo Gao、Xiaohui Jiang、Kenneth A. Jacobson
    DOI:10.1021/jm300965a
    日期:2012.9.27
    A(1) adenosine receptor (AR) agonists display antiischemic and antiepileptic neuroprotective activity, but peripheral cardiovascular side effects impeded their development. SAR study of N-6-cycloalkylmethyl 4'-truncated (N)-methanocarba-adenosines identified 10 (MRS5474, N-6-dicyclopropylmethyl, K-i = 47.9 nM) as a moderately A(1)AR-selective full agonist. Two stereochemically defined N-6-methynyl group substituents displayed narrow SAR; groups larger than cyclobutyl greatly reduced AR affinity, and those larger or smaller than cyclopropyl reduced A(1)AR selectivity. Nucleoside docking to A(1)AR homology model characterized distinct hydrophobic cyclopropyl subpockets, the larger "A" forming contacts with Thr270 (7.35), Tyr271 (7.36), Ile274 (7.39), and carbon chains of glutamates (EL2) and the smaller subpocket "B" forming contacts between TM6 and TM7. 10 suppressed minimal clonic seizures (6 Hz mouse model) without typical rotarod impairment of A(1)AR agonists. Truncated nucleosides, an appealing preclinical approach, have more druglike physicochemical properties than other A(1)AR agonists. Thus, we identified highly restricted regions for substitution around N-6 suitable for an A(1)AR agonist with anticonvulsant activity.
查看更多